# Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

> **NCT03107793** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 500 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT03107793
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-19
- **Primary completion:** 2020-04-30
- **Final completion:** 2021-07-20
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03107793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03107793, "Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03107793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*